Xeris Biopharma Holdings, Inc. (XERS) has 12 SEC Form 4 insider filings on record in the last 90 days. No insider purchases were filed — 9 sales totalling $1.8M. Most recent filing: Sept. 1, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Sept. 1, 2026 | Hecht Beth See Remarks | −$141,434 | 16,666 | −1% | Yes | |
|
|
||||||
| Sept. 1, 2026 | Pieper Steven See Remarks | −$42,500 | 5,000 | −0% | Yes | |
|
|
||||||
| Sept. 1, 2026 | McCulloch Kevin See Remarks | −$127,308 | 15,000 | −1% | Yes | |
|
|
||||||
| Aug. 21, 2026 filed Aug. 1, 2026 | Shannon John Patrick Jr See Remarks | $296,092 | 36,645 | −1% | No | |
|
|
||||||
| Aug. 21, 2026 filed Aug. 1, 2026 | McCulloch Kevin See Remarks | $177,097 | 21,918 | −1% | No | |
|
|
||||||
Showing the 5 most recent of 12 filings in the last 90 days.
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free